Physician profile
Lea Murphy
NPI 1336818905
$3,980.02
in general payments reported to CMS, 2019-2025
22 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.66 · 2022: $43.29 · 2023: $1,896 · 2024: $649 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,558 · Education: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,557.72 |
| Education | $364.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,101.53 | 2023-2025 | |
| Incyte Corporation | $465.26 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $425.84 | 2023-2025 | Tremfya |
| Dermavant Sciences, INC. | $263.78 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $199.88 | 2023-2025 | Sotyktu |
| Ucb, INC. | $191.45 | 2023-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $173.24 | 2021-2025 | |
| Genzyme Corporation | $152.15 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $135.92 | 2023-2025 | Ilumya, Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $132.82 | 2023-2025 | Zoryve |
| Amgen INC. | $130.07 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $120.01 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $109.00 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $79.21 | 2023 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $64.00 | 2023-2025 | Dupixent |
| Helsinn Therapeutics (U.S.), INC. | $39.21 | 2025 | Valchlor |
| Galderma Laboratories, L.P. | $35.22 | 2025 | Nemluvio |
| Organon LLC | $30.70 | 2025 | |
| Botanix Sb INC | $24.59 | 2025 | Sofdra |
| Lnhc, INC | $23.94 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.83 | 2023 | Jublia, Duobrii, Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.